Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Collins RH"" wg kryterium: Autor


Tytuł:
Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self-administered questionnaire to an initial screening platform.
Autorzy:
Zahid MF; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Department of Internal Medicine, Division of Hematology and Medical Oncology, Leukemia Program, UT Southwestern Medical Center, Dallas, Texas, USA.
Moriarty K; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Dryden C; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Weinberg O; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Asif M; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Ikpefan R; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Anderson JM; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Collins RH; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Department of Internal Medicine, Division of Hematology and Medical Oncology, Leukemia Program, UT Southwestern Medical Center, Dallas, Texas, USA.
Chung SS; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Department of Internal Medicine, Division of Hematology and Medical Oncology, Leukemia Program, UT Southwestern Medical Center, Dallas, Texas, USA.
Chen W; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Patel PA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Department of Internal Medicine, Division of Hematology and Medical Oncology, Leukemia Program, UT Southwestern Medical Center, Dallas, Texas, USA.
Madanat YF; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Department of Internal Medicine, Division of Hematology and Medical Oncology, Leukemia Program, UT Southwestern Medical Center, Dallas, Texas, USA.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2023 Dec; Vol. 111 (6), pp. 844-850. Date of Electronic Publication: 2023 Aug 16.
Typ publikacji:
Journal Article
MeSH Terms:
Myeloproliferative Disorders*/genetics
Neoplasms*
Humans ; Middle Aged ; Genetic Predisposition to Disease ; Mutation ; Germ-Line Mutation ; Syndrome
Czasopismo naukowe
Tytuł:
Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report.
Autorzy:
Hoff FW; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Rolwes J; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Hardeman PA; Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA.
Perkins M; Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Major EO; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Douek D; Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Collins RH Jr; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8806, USA.
Greenberg BM; Department of Neurology, O'Donnell Brain Institute, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8806, USA.
Pokaż więcej
Źródło:
Therapeutic advances in hematology [Ther Adv Hematol] 2023 Oct 09; Vol. 14, pp. 20406207231201721. Date of Electronic Publication: 2023 Oct 09 (Print Publication: 2023).
Typ publikacji:
Case Reports
Raport
Tytuł:
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Autorzy:
Duong VH; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
Ruppert AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Mims AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Borate U; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Stein EM; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
Stock W; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Kovacsovics T; Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah, USA.
Blum W; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Arellano ML; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Schiller GJ; David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Olin RL; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, USA.
Foran JM; Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
Litzow MR; Departments of Medical Oncology, Hematology, and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Lin TL; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
Patel PA; University of Texas Southwestern Medical Center Medical School, Dallas, Texas, USA.
Foster MC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Redner RL; Hillman Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Al-Mansour Z; Department of Medicine, University of Florida, Gainesville, Florida, USA.
Cogle CR; Department of Medicine, University of Florida, Gainesville, Florida, USA.
Swords RT; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Collins RH; University of Texas Southwestern Medical Center Medical School, Dallas, Texas, USA.
Vergilio JA; Foundation Medicine, Cambridge, Massachusetts, USA.
Heerema NA; Department of Pathology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Rosenberg L; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
Yocum AO; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
Marcus S; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
Chen T; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Druggan F; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Stefanos M; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Gana TJ; Biopharmatech Consulting, Inc., Leesburg, Virginia, USA.
Shoben AB; Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, Ohio, USA.
Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
Burd A; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
Byrd JC; Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Levine RL; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Boyiadzis MM; Hillman Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Pokaż więcej
Źródło:
Cancer [Cancer] 2023 Aug 01; Vol. 129 (15), pp. 2308-2320. Date of Electronic Publication: 2023 Apr 20.
Typ publikacji:
Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Tumor Suppressor Protein p53*/genetics
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/pathology
Humans ; Decitabine ; Karyotype ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Autorzy:
Hoff FW; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Chung SS; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Patel PA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Premnath N; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Khatib J; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Tadic-Ovcina M; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
AhmedRabie A; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Helton D; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Yohannes S; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Shahan J; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Patel H; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Geethakumari PR; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Vusirikala M; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Collins RH; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America.
Madanat YF; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States of America. Electronic address: .
Pokaż więcej
Źródło:
Transplant immunology [Transpl Immunol] 2023 Apr; Vol. 77, pp. 101808. Date of Electronic Publication: 2023 Feb 24.
Typ publikacji:
Journal Article
MeSH Terms:
Cyclophosphamide*/administration & dosage
Cyclophosphamide*/therapeutic use
Chimerism*
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/pathology
Leukemia, Myeloid, Acute*/therapy
Myelodysplastic Syndromes*/pathology
Myelodysplastic Syndromes*/therapy
Transplantation, Homologous ; Graft vs Host Disease/prevention & control ; Recurrence ; Electronic Health Records ; Retrospective Studies ; Transplantation Conditioning ; Risk Assessment ; Humans ; Male ; Female ; Young Adult ; Adult ; Middle Aged ; Aged ; Survival Rate ; Regression Analysis
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies